Leerink Partnrs Has Negative Outlook of MLTX FY2025 Earnings
MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) – Stock analysts at Leerink Partnrs reduced their FY2025 earnings estimates for MoonLake Immunotherapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($3.22) per share for the year, down from their prior estimate of […]
More Stories
Massive Alaska North Slope Gas Discovery Could Power US for Nearly 3 Years
By Naveen Athrappully Alaska’s North Slope region could contain 96 trillion cubic feet of undiscovered and technically recoverable natural gas...
UK Must Be Ready for War in 1,000 Days, Says British Defense Secretary
By Rachel Roberts British Defense Secretary Wes Streeting has said the country must be ready for war in 1,000 days,...
Trump Offers $1 Million to Anyone Who Reports Voter Fraud Leading to Conviction
By Jack Phillips President Donald Trump on Monday said that he would provide $1 million to people who can report...
Federal Judge Strikes Down New York Body Armor Ban
By Jack Phillips A federal judge this past week overturned New York state’s ban on the sale and purchase of...
Anthropic Files Blockbuster IPO
By Andrew Moran Anthropic, the company behind Claude, is set to make its long-awaited Wall Street debut as soon as...
How Inventory Allocation Across Multiple Warehouses Can Reduce Delivery Times and Costs
A shopper in Seattle orders a pair of running shoes. Whether that package arrives quickly and cheaply depends on a...